^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABBV-706
i
Other names: ABBV-706, ABBV706, ABBV 706
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie
Drug class:
Topoisomerase I inhibitor, SEZ6-targeted antibody-drug conjugate
Related drugs:
8ms
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=350, Recruiting, AbbVie | Trial completion date: Oct 2025 --> May 2027
Trial completion date • Adverse events • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
|
EGFR mutation • IDH wild-type • SEZ6 expression
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
9ms
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=350, Recruiting, AbbVie | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025
Trial completion date • Trial primary completion date • Adverse events • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
|
EGFR mutation • IDH wild-type • SEZ6 expression
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
over1year
Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors (ESMO 2023)
The study will evaluate the preliminary safety, tolerability, pharmacokinetics (PK), and antitumor activity of ABBV-706 as monotherapy and in combination with budigalimab (a PD-1 inhibitor), carboplatin, or cisplatin, and determine the recommended phase 2 dose (RP2D) of ABBV-706. Tumor tissue submission for retrospective SEZ6 expression analysis is required. The study began in December 2022 and enrollment is ongoing.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
SEZ6 (Seizure Related 6 Homolog)
|
SEZ6 expression
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
2years
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=350, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • IDH wild-type
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
2years
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=350, Not yet recruiting, AbbVie
New P1 trial • Adverse events • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • IDH wild-type
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
Share via
